Furthermore, ORIENT-31 is a phase III randomized clinical trial evaluating the efficacy of combination therapy with Sintilimab, a PD-1 inhibitor, with or without a Bevacizumab biosimilar, in addition to platinum-based chemotherapy, for patients with advanced EGFR-mutant NSCLC who have progressed after prior EGFR-TKI therapy [30]. Here, EGFR is linked to non-small cell lung carcinoma.